$$News and Reports$$

May. 19, 2019


Bone Sci Bio introduces PeptOss, a novel solution for bone treatment. The new product promotes formation and repair of bone tissue and enables controlled delivery of drugs, such as antibiotics or chemotherapy, directly to the bone, for various orthopedic and dental applications. The newly founded Bone Sci Bio Ltd. will present its novel solution at the MIXiii-BIOMED 2019 Conference and Exhibition, taking place on May 14-16 at the David InterContinental Hotel in Tel Aviv.   

The dual function of PeptOss, promoting superior bone regeneration as well as enabling extended drug delivery, renders it a promising, novel bone treatment for diverse indications in orthopedic and dental medicine. The first application is for antibiotic-loaded preparation for treating peri-implantitis, the destructive inflammatory process damaging the hard tissue surrounding dental implants, which affects 30% of patients who receive dental implants, within 10 years of implantation. Future applications include strengthening osteoporotic bones to prevent high risk hip fractures, as well as loading PeptOss with chemotherapeutic drugs for the treatment of osteosarcoma, rendering increased effectivity combined with reduced toxicity.


​PeptOss, invented by Prof. Hanna Rapaport, the Avram and Stella Goldstein-Goren Department of Biotechnology Engineering at Ben-Gurion University of the Negev, comprises a short, proprietary peptide, PFD5 that mimics certain proteins of the bone extracellular matrix. PFD5 self-assembles as a hydrogel and together with calcium phosphate particles, induces biomineralization of hydroxyapatite, an essential ingredient that gives bones their rigidity. PeptOss can also be preloaded with a desired drug for sustained release over a period of several weeks directly to the implantation site. The technology was patented by BGN Technologies, BGU's technology transfer company.  

In pre-clinical trials, PFD5 has been shown to promote bone regeneration and to improve integration of new bone with the preexisting tissue, and its performance was up to 80% better than the control. 

“Our unique technology platform allows us to embrace a “holistic approach" in bone treatment, way beyond the plethora of “bone void fillers" which currently dominate the $4.5B bone substitutes market," said Co-Founder and CEO Yaron Rapaport. “While clinical studies are yet to be performed in order to gain an FDA approval, our breakthrough solution to peri-implantitis is much anticipated by dentists around the world, acknowledging that PeptOss addresses an unmet need and presents a clear competitive edge."